Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QAX576 in perianal fistulas in Crohn's disease
NCT01355614Phase 2Completed
- Sponsor
- Novartis
- Start
- Jun 2011
- Primary completion
- Mar 2013
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of dectrekumab in Crohn's disease (2 arms), sponsored by Novartis. Primary endpoint: Complete closure of all perianal fistulas at 52 weeks. Started Jun 2011; status: completed.
02
Drugs
dectrekumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT01355614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01355614.